Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aic246
2. Prevymis
1. 917389-32-3
2. Aic246
3. Prevymis
4. Aic-246
5. Aic 246
6. Mk-8228
7. 1h09y5wo1f
8. 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetic Acid
9. 2-((4s)-8-fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4h-quinazolin-4-yl)acetic Acid
10. 4-quinazolineacetic Acid, 8-fluoro-3,4-dihydro-2-(4-(3-methoxyphenyl)-1-piperazinyl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-, (4s)-
11. Letermovir [inn]
12. Letermovir [usan:inn]
13. Unii-1h09y5wo1f
14. Prevymis (tn)
15. (s)-[8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazoline-4-yl]acetic Acid
16. (s)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazoline-4-yl}acetic Acid
17. Mk-8828
18. Letermovir(aic246)
19. Letermovir [mi]
20. Letermovir [jan]
21. Letermovir [usan]
22. Letermovir [who-dd]
23. Letermovir (jan/usan/inn)
24. Schembl379403
25. Chembl1241951
26. Letermovir [orange Book]
27. Dtxsid40238683
28. Ex-a1871
29. S8873
30. Zinc100369359
31. Cs-1571
32. Db12070
33. Aic246;aic 246;aic-246
34. Ncgc00378936-01
35. Ncgc00378936-02
36. Ac-35698
37. As-56206
38. Hy-15233
39. J3.556.145e
40. D10801
41. D71052
42. A902281
43. Q15409407
44. (4s)-2-(8-fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-4-yl)acetic Acid
45. (4s)-8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic Acid
46. (s)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydro-quinazolin-4-yl}acetic Acid
47. (s)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazolin-4-yl}acetic Acid
48. (s)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic Acid
Molecular Weight | 572.5 g/mol |
---|---|
Molecular Formula | C29H28F4N4O4 |
XLogP3 | 4.6 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 7 |
Exact Mass | 572.20466804 g/mol |
Monoisotopic Mass | 572.20466804 g/mol |
Topological Polar Surface Area | 77.8 Ų |
Heavy Atom Count | 41 |
Formal Charge | 0 |
Complexity | 931 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For use in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
FDA Label
Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).
Consideration should be given to official guidance on the appropriate use of antiviral agents.
Letermovir inhibits the activity of the DNA terminase complex of CMV thereby preventing the cutting of viral DNA into mature length genomes for packaging into viral particles. Letemovir inhibits the DNA terminase complex with an EC50 of 2.1nM.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Poly(ADP-ribose) Polymerase Inhibitors
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)
J05
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AX - Other antivirals
J05AX18 - Letermovir
Absorption
Letermovir has a bioavailability of 94% in healthy subjects when administered without cyclosporin, 35% in HSCT recipients when administered without cyclosporin, and 85% in HSCT recipients when administered with cyclosporin. Letermovir's Tmax is 45 min to 2.25 h. Time to steady state has been observed to be 9-10 days. Taking Letermovir with food increases Cmax by an average of 129.82% (range of 104.35%-161.50%). No significant effect on AUC has been observed .
Route of Elimination
Letemovir is taken up by the liver through OATP1B1/3 transporters. 93% is excreted in the feces with 70% as the parent drug. <2% is excreted in the urine.
Volume of Distribution
The mean steady state volume of distrubution is 45.5L
Clearance
The mean clearance is 11.25 L/h in healthy subjects
Letermovir undergoes a minor degree of metabolism through UGT1A1/1A3.
The mean terminal half-life was observed to be 12 hours following administration of Letemovir 480 mg IV once daily.
CMV relies on a DNA terminase complex consisting of multiple subunits (pUL51, pUL56, and pUL89) for processing of viral DNA. Viral DNA is produced in a single repeating strand which is then cut by the DNA terminase complex into individual viral genomes which can then be packaged into mature viral particles. Letemovir inhibits the activity of this complex to prevent production of mature viral genomes and the production of viable viral particles. The exact nature of Letemovir's binding to this complex is not currently known. Initially, the observation of resistance-causing mutations in pUL56 suggested this subunit was the location of Letemovir binding. However, resistance mutations have now been observed in pUL51, pUL56, and pUL89. It is possible that changes in amino acid sequence in one subunit could result in conformational changes to interacting subunits affecting Letemovir binding or that Letemovir interacts with multiple subunits of the complex but evidence towards either of these distinctions has not yet been seen. pUL89 is known to contain the endonuclease activity of the complex but because all members of the complex are necessary for targeting as well as protection from proteosomal degradation, it is difficult to discern if Letemovir inhibits pUL89's activity directly.
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
Date of Issue : 2024-08-28
Valid Till : 2027-08-27
Written Confirmation Number : SD240048
Address of the Firm :
Registrant Name : Sampoong Pharmachem Co., Ltd.
Registration Date : 2025-03-11
Registration Number : Su582-25-ND
Manufacturer Name : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd
Manufacturer Address : Economic Development Zone, Pingyuan County, Dezhou City, Shandong, PRChina
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41441
Submission : 2025-06-29
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39852
Submission : 2024-04-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40787
Submission : 2024-11-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41229
Submission : 2025-01-21
Status : Active
Type : II
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41441
Submission : 2025-06-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39852
Submission : 2024-04-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-07-06
Pay. Date : 2021-06-16
DMF Number : 35981
Submission : 2021-06-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41229
Submission : 2025-01-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40787
Submission : 2024-11-22
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-09-29
Pay. Date : 2021-09-17
DMF Number : 36024
Submission : 2021-06-19
Status : Active
Type : II
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
Date of Issue : 2024-08-28
Valid Till : 2027-08-27
Written Confirmation Number : SD240048
Address of the Firm : Economic Development Zone, Pingyuan County, Dezhou City, Shandong
About the Company : Lebsa is an innovative European laboratory that specializes in the synthesis, manufacture and commercialization of APIs with a focus on niche products. With a track record spanning...
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates, CDMO/CRO/OEM, and Technology Transfer of Finished Formulat...
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
About the Company : Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standar...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Globe Quimica S.A. is a major Brazilian API producer, GMP certificated by ANVISA, manufactures more than 20 different API's such as Antiretrovirals, Anxiolytic, Antidepressant, Ant...
About the Company : Nantong Jinghua Pharmaceutical is a public pharmaceutical company that was established in 1957, owns about 302 staff, located in No. 20, 3 Haibin Road, Yanhai Economic Development ...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Failure, Chronic.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Jason A Roberts | Royal Brisbane and Women's Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2025
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Jason A Roberts | Royal Brisbane and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
PK of Oral Letermovir in Adults with End-Stage Kidney Disease With/Without Dialysis
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2025
Details:
Anvimo (letermovir), is CMV DNA terminase inhibitor small molecule drug candidate, which is indicated for the treatment of cytomegalovirus infection.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Anvimo
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 06, 2025
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences Launches Anvimo
Details : Anvimo (letermovir), is CMV DNA terminase inhibitor small molecule drug candidate, which is indicated for the treatment of cytomegalovirus infection.
Product Name : Anvimo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2025
Details:
Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 09, 2024
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2024
Details:
Prevymis (letermovir) is a CMV DNA terminase complex inhibitor small molecule drug candidate, which is indicated for cytomegalovirus disease in high-risk adult kidney transplant recipients.
Lead Product(s): Letermovir,Acyclovir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Prevymis
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 19, 2024
Lead Product(s) : Letermovir,Acyclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Approves PREVYMIS for CMV Disease Prevention in High-Risk Kidney Transplant
Details : Prevymis (letermovir) is a CMV DNA terminase complex inhibitor small molecule drug candidate, which is indicated for cytomegalovirus disease in high-risk adult kidney transplant recipients.
Product Name : Prevymis
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2024
Details:
Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex, which is indicated for the treatment of Cytomegalovirus.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Prevymis
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2023
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk ...
Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex, which is indicated for the treatment of Cytomegalovirus.
Product Name : Prevymis
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2023
Details:
Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2023
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2023
Details:
Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2023
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2023
Details:
Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft Rejection.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2023
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft Rejection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2023
Details:
Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex and FDA Approves New Indication forCytomegalovirus.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Prevymis
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2023
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves New Indication for Merck’s PREVYMIS (letermovir) for Prevention of Cytomegalov...
Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex and FDA Approves New Indication forCytomegalovirus.
Product Name : Prevymis
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2023
Details:
Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.
Lead Product(s): Letermovir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2023
Lead Product(s) : Letermovir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2023
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Injectable / Parenteral
Grade : Oral, Parenteral
Dosage Form : Tablet
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
72
PharmaCompass offers a list of Letermovir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Letermovir manufacturer or Letermovir supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Letermovir manufacturer or Letermovir supplier.
PharmaCompass also assists you with knowing the Letermovir API Price utilized in the formulation of products. Letermovir API Price is not always fixed or binding as the Letermovir Price is obtained through a variety of data sources. The Letermovir Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Letermovir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Letermovir, including repackagers and relabelers. The FDA regulates Letermovir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Letermovir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Letermovir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Letermovir supplier is an individual or a company that provides Letermovir active pharmaceutical ingredient (API) or Letermovir finished formulations upon request. The Letermovir suppliers may include Letermovir API manufacturers, exporters, distributors and traders.
click here to find a list of Letermovir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Letermovir DMF (Drug Master File) is a document detailing the whole manufacturing process of Letermovir active pharmaceutical ingredient (API) in detail. Different forms of Letermovir DMFs exist exist since differing nations have different regulations, such as Letermovir USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Letermovir DMF submitted to regulatory agencies in the US is known as a USDMF. Letermovir USDMF includes data on Letermovir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Letermovir USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Letermovir suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Letermovir Drug Master File in Korea (Letermovir KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Letermovir. The MFDS reviews the Letermovir KDMF as part of the drug registration process and uses the information provided in the Letermovir KDMF to evaluate the safety and efficacy of the drug.
After submitting a Letermovir KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Letermovir API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Letermovir suppliers with KDMF on PharmaCompass.
A Letermovir written confirmation (Letermovir WC) is an official document issued by a regulatory agency to a Letermovir manufacturer, verifying that the manufacturing facility of a Letermovir active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Letermovir APIs or Letermovir finished pharmaceutical products to another nation, regulatory agencies frequently require a Letermovir WC (written confirmation) as part of the regulatory process.
click here to find a list of Letermovir suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Letermovir as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Letermovir API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Letermovir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Letermovir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Letermovir NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Letermovir suppliers with NDC on PharmaCompass.
Letermovir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Letermovir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Letermovir GMP manufacturer or Letermovir GMP API supplier for your needs.
A Letermovir CoA (Certificate of Analysis) is a formal document that attests to Letermovir's compliance with Letermovir specifications and serves as a tool for batch-level quality control.
Letermovir CoA mostly includes findings from lab analyses of a specific batch. For each Letermovir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Letermovir may be tested according to a variety of international standards, such as European Pharmacopoeia (Letermovir EP), Letermovir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Letermovir USP).